Ondine Biomedical Inc. (OBI.L) LSE

8.75

+0.15(+1.74%)

Updated at December 24 10:12AM

Currency In GBp

Ondine Biomedical Inc.

Address

1100 Melville Street

Vancouver, BC V6E 4A6

Canada

Phone

604-669-0555

Sector

Healthcare

Industry

Biotechnology

Employees

18

First IPO Date

December 06, 2021

Key Executives

NameTitlePayYear Born
Carolyn CrossFounder, Chief Executive Officer & Executive Director895,248N/A
Nicolas G. LoebelPresident, Chief Technology Officer & Executive Director718,846N/A
Alan ThomasNon-Board Interim Chief Financial Officer0N/A
Matt RossVice President of Sales & Marketing0N/A
Nikita ParkevVice President of Finance & Company Secretary0N/A
William KanzSenior Vice President of Engineering & Operations0N/A
Angelika VanceVice President of Corporate Communications0N/A
Elaine LeiCorporate Controller & Company Secretary0N/A

Description

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.